Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®

PHASE3CompletedINTERVENTIONAL
Enrollment

1,134

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

Tiotropium

Marketed dose

DRUG

Placebo matching Olodaterol

One dose

DRUG

Olodaterol

One dose

DRUG

Tiotropium

Marketed dose

Trial Locations (90)

Unknown

1222.51.01055 Boehringer Ingelheim Investigational Site, Florence

1222.51.01087 Boehringer Ingelheim Investigational Site, Jasper

1222.51.01066 Boehringer Ingelheim Investigational Site, Phoenix

1222.51.01069 Boehringer Ingelheim Investigational Site, Scottsdale

1222.51.01040 Boehringer Ingelheim Investigational Site, Anaheim

1222.51.01064 Boehringer Ingelheim Investigational Site, Encinitas

1222.51.01060 Boehringer Ingelheim Investigational Site, Fullerton

1222.51.01084 Boehringer Ingelheim Investigational Site, Lincoln

1222.51.01041 Boehringer Ingelheim Investigational Site, San Diego

1222.51.01094 Boehringer Ingelheim Investigational Site, San Diego

1222.51.01015 Boehringer Ingelheim Investigational Site, Torrance

1222.51.01052 Boehringer Ingelheim Investigational Site, Boulder

1222.51.01010 Boehringer Ingelheim Investigational Site, Wheat Ridge

1222.51.01042 Boehringer Ingelheim Investigational Site, Wheat Ridge

1222.51.01070 Boehringer Ingelheim Investigational Site, Stamford

1222.51.01006 Boehringer Ingelheim Investigational Site, Clearwater

1222.51.01021 Boehringer Ingelheim Investigational Site, Clearwater

1222.51.01082 Boehringer Ingelheim Investigational Site, Clearwater

1222.51.01065 Boehringer Ingelheim Investigational Site, DeLand

1222.51.01051 Boehringer Ingelheim Investigational Site, Jacksonville

1222.51.01092 Boehringer Ingelheim Investigational Site, Jacksonville

1222.51.01081 Boehringer Ingelheim Investigational Site, Ormond Beach

1222.51.01054 Boehringer Ingelheim Investigational Site, Panama City

1222.51.01062 Boehringer Ingelheim Investigational Site, Pensacola

1222.51.01088 Boehringer Ingelheim Investigational Site, Port Orange

1222.51.01079 Boehringer Ingelheim Investigational Site, Tamarac

1222.51.01075 Boehringer Ingelheim Investigational Site, Atlanta

1222.51.01076 Boehringer Ingelheim Investigational Site, Austell

1222.51.01057 Boehringer Ingelheim Investigational Site, Duluth

1222.51.01086 Boehringer Ingelheim Investigational Site, Lawrenceville

1222.51.01019 Boehringer Ingelheim Investigational Site, Coeur d'Alene

1222.51.01027 Boehringer Ingelheim Investigational Site, Eagle

1222.51.01048 Boehringer Ingelheim Investigational Site, Arlingron Heights

1222.51.01044 Boehringer Ingelheim Investigational Site, River Forest

1222.51.01043 Boehringer Ingelheim Investigational Site, Skokie

1222.51.01090 Boehringer Ingelheim Investigational Site, Louisville

1222.51.01023 Boehringer Ingelheim Investigational Site, Lafayette

1222.51.01071 Boehringer Ingelheim Investigational Site, Opelousas

1222.51.01050 Boehringer Ingelheim Investigational Site, North Dartmouth

1222.51.01049 Boehringer Ingelheim Investigational Site, Ann Arbor

1222.51.01025 Boehringer Ingelheim Investigational Site, Livonia

1222.51.01078 Boehringer Ingelheim Investigational Site, Edina

1222.51.01033 Boehringer Ingelheim Investigational Site, Fridley

1222.51.01074 Boehringer Ingelheim Investigational Site, Saint Charles

1222.51.01037 Boehringer Ingelheim Investigational Site, St Louis

1222.51.01039 Boehringer Ingelheim Investigational Site, Reno

1222.51.01045 Boehringer Ingelheim Investigational Site, Larchmont

1222.51.01018 Boehringer Ingelheim Investigational Site, Rochester

1222.51.01014 Boehringer Ingelheim Investigational Site, Asheville

1222.51.01077 Boehringer Ingelheim Investigational Site, Charlotte

1222.51.01056 Boehringer Ingelheim Investigational Site, Greensboro

1222.51.01032 Boehringer Ingelheim Investigational Site, Canton

1222.51.01011 Boehringer Ingelheim Investigational Site, Cincinnati

1222.51.01005 Boehringer Ingelheim Investigational Site, Columbus

1222.51.01093 Boehringer Ingelheim Investigational Site, Dayton

1222.51.01089 Boehringer Ingelheim Investigational Site, Sylvania

1222.51.01080 Boehringer Ingelheim Investigational Site, Toledo

1222.51.01017 Boehringer Ingelheim Investigational Site, Oklahoma City

1222.51.01047 Boehringer Ingelheim Investigational Site, Tulsa

1222.51.01031 Boehringer Ingelheim Investigational Site, Corvallis

1222.51.01020 Boehringer Ingelheim Investigational Site, Medford

1222.51.01053 Boehringer Ingelheim Investigational Site, Portland

1222.51.01016 Boehringer Ingelheim Investigational Site, Erie

1222.51.01004 Boehringer Ingelheim Investigational Site, Philadelphia

1222.51.01030 Boehringer Ingelheim Investigational Site, East Providence

1222.51.01009 Boehringer Ingelheim Investigational Site, Johnston

1222.51.01036 Boehringer Ingelheim Investigational Site, Charleston

1222.51.01061 Boehringer Ingelheim Investigational Site, Columbia

1222.51.01038 Boehringer Ingelheim Investigational Site, Easley

1222.51.01046 Boehringer Ingelheim Investigational Site, Easley

1222.51.01022 Boehringer Ingelheim Investigational Site, Gaffney

1222.51.01063 Boehringer Ingelheim Investigational Site, Greenville

1222.51.01013 Boehringer Ingelheim Investigational Site, Greer

1222.51.01024 Boehringer Ingelheim Investigational Site, Spartanburg

1222.51.01012 Boehringer Ingelheim Investigational Site, Union

1222.51.01008 Boehringer Ingelheim Investigational Site, Rapid City

1222.51.01035 Boehringer Ingelheim Investigational Site, Johnson City

1222.51.01028 Boehringer Ingelheim Investigational Site, Boerne

1222.51.01083 Boehringer Ingelheim Investigational Site, Corsicana

1222.51.01085 Boehringer Ingelheim Investigational Site, Killeen

1222.51.01073 Boehringer Ingelheim Investigational Site, Longview

1222.51.01003 Boehringer Ingelheim Investigational Site, San Antonio

1222.51.01058 Boehringer Ingelheim Investigational Site, Murray

1222.51.01068 Boehringer Ingelheim Investigational Site, Abingdon

1222.51.01029 Boehringer Ingelheim Investigational Site, Richmond

1222.51.01034 Boehringer Ingelheim Investigational Site, Richmond

1222.51.01072 Boehringer Ingelheim Investigational Site, Richmond

1222.51.01091 Boehringer Ingelheim Investigational Site, Spokane

1222.51.01002 Boehringer Ingelheim Investigational Site, Vancouver

1222.51.01001 Boehringer Ingelheim Investigational Site, Morgantown

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT01694771 - Co-administration of Olodaterol Respimat® and Tiotropium Handihaler® | Biotech Hunter | Biotech Hunter